Enalapril Maleate Tablets (10mg*8 tablets)

This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension.

The main ingredient of this product is: Enalapril Maleate.

This product is white tablets.

Essential hypertension of all stages; renovascular hypertension; heart failure of all levels. For patients with symptomatic heart failure, this product is also suitable for improving the survival rate, delaying the progression of symptomatic heart failure, and reducing hospitalizations due to heart failure; preventing symptomatic heart failure. For patients with asymptomatic left ventricular dysfunction, it prevents coronary ischemic events in patients with left ventricular dysfunction. This product is suitable for reducing the incidence of myocardial infarction and reducing hospitalizations caused by unstable angina.

The starting dose is 5-10 mg per day, taken orally in 1-2 times. For patients with severe renal impairment (creatinine clearance less than 30 ml/min), the dose is 2.5 mg per day. The dose can be gradually increased according to the blood pressure level. The general effective dose is 10-20 mg per day. The maximum daily dose should not exceed 40 mg. It can be used in combination with other antihypertensive drugs, especially diuretics, and the antihypertensive effect is significantly enhanced, but it should not be used in combination with potassium-retaining diuretics.

Symptoms may include dizziness, headache, drowsiness, dry mouth, fatigue, upper abdominal discomfort, nausea, palpitations, chest tightness, cough, flushing, rash, and proteinuria. Reduce the dosage if necessary. If leukopenia occurs, stop taking the drug.

Patients who are allergic to this product or have bilateral renal artery stenosis should not use this product. Patients with severe renal impairment should use it with caution.

Precautions for children: This product has not been studied for use in children. Precautions for pregnancy and lactation: Pregnancy 1. This drug is not recommended for use during pregnancy. If pregnancy is confirmed, use of this product should be stopped immediately unless it is necessary to save the mother's life. 2. Angiotensin-converting enzyme inhibitors used during the second and third trimesters of pregnancy can cause morbidity and death in the fetus and newborn. The use of angiotensin-converting enzyme inhibitors during this period is associated with various injuries to the fetus and newborn (including hypotension, renal failure, hyperkalemia, and/or incomplete cranial development of the newborn). There have been cases of maternal oligohydramnios (presumably a manifestation of reduced fetal renal function) and can lead to limb spasms, craniofacial malformations, and pulmonary dysplasia. If the patient uses this product, the patient should be informed of its potential harm to the fetus. 3. The use of the drug in the first three months of pregnancy to expose the uterus to this angiotensin-converting enzyme inhibitor will not cause the above-mentioned adverse reactions in the embryo and fetus. 4. In those rare cases where angiotensin converting enzyme inhibitors must be used during pregnancy, a series of ultrasound examinations should be performed to evaluate the situation in the amniotic membrane. If oligohydramnios is found, this product should be discontinued unless it is necessary to save the mother's life. Patients and doctors should be aware that when oligohydramnios occurs, the fetus has suffered irreversible damage. 5. Infants born to mothers who have used this product should be closely observed to find out whether they have hypotension, oliguria and hyperkalemia. Enalapril can pass through the placenta. Peritoneal dialysis can clear it from the fetal blood circulation, which is clinically beneficial. In theory, it can be removed by exchange transfusion. Enalapril and enalaprilat (the hydrolysis product of enalapril) are secreted in small amounts in human milk by breastfeeding mothers. Breastfeeding mothers should be cautious when using this product. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

Not yet clear.

Keep away from light and store in a sealed container.

5 mg

36 months

Shanghai Shyndec Pharmaceutical Co., Ltd.

• Founded in:

  1996-11-27

• Address:

  No. 378, Jianlu Road, Pudong New Area, Shanghai

• Tax NO.:

  91310000630459924R

• Registered Funds:

  1,341,172,692 yuan

• Website:

  Log in to view

• Email:

  Log in to view